Corrigendum: Eligibility for clinical trials in primary Sjögren's syndrome: Lessons from the UK Primary Sjögren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373;Eligibility for clinical trials in primary sjögren's syndrome: Lessons from the UK primary sjögren's syndrome registry

Rheumatology (United Kingdom)

Volumn 55, Issue 3, 2016, Pages 544-552

  Oni, Clare ^a   Mitchell, Sheryl ^b   James, Katherine ^c   Ng, Wan Fai ^b,d   Griffiths, Bridget ^b   Hindmarsh, Victoria ^b   Price, Elizabeth ^e   Pease, Colin T ^f,g   Emery, Paul ^f,g   Lanyon, Peter ^h   Jones, Adrian ^h   Bombardieri, Michele ⁱ   Sutcliffe, Nurhan ⁱ   Pitzalis, Costantino ⁱ   Hunter, John ^j   Gupta, Monica ^j   McLaren, John ^k   Cooper, Annie ^l   Regan, Marian ^m   Giles, Ian ⁿ   Isenberg, David ⁿ   Saravanan, Vadivelu ^o   Coady, David ^p   Dasgupta, Bhaskar ^q   McHugh, Neil ^r   Young Min, Steven ^s   Moots, Robert ^t   Gendi, Nagui ^u   Barone, Francesca ^v   Fisher, Ben ^w   Rauz, Saaeha ^w   Richards, Andrea ^x   Bowman, Simon J ^a   Bacabac, Elalaine C ^t   Chadravarty, Kuntal ^y   Lamabadusuriya, Shamin ^y   Adeniba, Rashidat ⁱ   Hamburger, John ^u   Higham, Jon ^x   Poveda Galego, Ana ^x   Logan, Joanne ^x   Mulherin, Diarmuid ^x   Andrews, Jacqueline ^z   McManus, Alison ^z   Booth, Alison ^aa   Dimitroulas, Theodoros ^ab   Kadiki, Lucy ^ac   Kaur, Daljit ^ac   Kitas, George ^ac   Lloyd, Mark ^ac   Moore, Lisa ^ac   Gordon, Esther ^ad   Lawson, Cathy ^ad   Stirton, Lesley ^j   Ortiz, Gill ^ae   Clunie, Gavin ^af   Cuckow, Sue ^af   Rose, Ginny ^af   Jones, Beverley ^ag   Knight, Susan ^ag   Symmons, Deborah ^ag   Carr, Andrew ^c   Carrozzo, Marco ^c   Edgar, Suzanne ^c   Figuereido, Francisco ^c   Foggo, Heather ^c   Gillespie, Colin ^c   Lendrem, Dennis ^c   Macleod, Iain ^c   Tarn, Jessica ^c   Muir, Alice ^h   White, Paula ^s   Pugmire, Susan ^o   Watkins, Marianne ^l   Field, Anne ^ah   Kaye, Stephen ^ah   Medcalf, Patricia ^ah   Mewar, Devesh ^ah   Tomlinson, Pamela ^ah   Whiteside, Debbie ^ah   James, Julie ^r   Pauling, John ^r   Olaitan, Nike ^r   Akil, Mohammed ^v   Godia, Olivia ^v   McDermott, Jayne ^v   Kidd, Elizabeth ^p   Palmer, Lynne ^p   Katsande, Victoria ^q   Long, Pamela ^q   Chandra, Usha ^ai   MacKay, Kirsten ^ai   Fedele, Stefano ⁿ   Ferenkeh Koroma, Ada ⁿ   Marconnell, Helena ⁿ   Porter, Stephen ⁿ   Brailsford, Sue ^a   Allcoat, Paul ^k   more..

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e GREAT WESTERN HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁱ BARTS HEALTH NHS TRUST   (United Kingdom)

^j GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^k NHS FIFE   (United Kingdom)

^l ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^m ROYAL DERBY HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^o QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^p SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^q SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^r ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^s PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^t ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^u BASILDON HOSPITAL   (United Kingdom)

^v ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^w UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^x BIRMINGHAM DENTAL HOSPITAL   (United Kingdom)

^y HAVERING AND REDBRIDGE UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^z CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^aa DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^ab DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^ac FRIMLEY PARK HOSPITAL   (United Kingdom)

^ad HARROGATE AND DISTRICT NHS FOUNDATION TRUST   (United Kingdom)

^ae GREAT WESTERN HOSPITAL   (United Kingdom)

^af IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^ag MACCLESFIELD DISTRICT GENERAL HOSPITAL   (United Kingdom)

^ah ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^ai TORBAY HOSPITAL   (United Kingdom)

more..

Author keywords

Clinical trial; Eligibility; Registry; Sj gren's

Indexed keywords

ABATACEPT; BELIMUMAB; IMMUNOGLOBULIN G; INFLIXIMAB; LA ANTIBODY; PILOCARPINE; PREDNISOLONE; RITUXIMAB; RO ANTIBODY; TOCILIZUMAB;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; EULAR SJOGREN SYNDROME DISEASE ACTIVITY INDEX; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY SJOGREN SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALIVATION; SJOEGREN SYNDROME; SJOGREN SYNDROME PATIENT REPORTED INDEX; SYNDROME; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84965064785     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex331     Document Type: Erratum

References (28)

1. Jonsson R, Bowman SJ, Gordon TP. Sjogren's syndrome. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions, 15th edn. Philadelphia, USA: Lippincott Williams & Wilkins, 2005: 1681-705.
2. Bowman SJ, Booth DA, Platts RG, UK Sjögren's Interest Group. Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire tool. Rheumatology 2004;43:758-64.
3. Ramos-Casals M, Brito-Zero P, Solans R et al. Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 2014;53:321-31.
4. Theander E, Vasaitis L, Baecklund E et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011;70:1363-8.
5. Sada PR, Isenberg D, Ciurtin C. Biologic treatment in Sjögren's syndrome. Rheumatology 2015;54:219-30.
6. Mariette X, Ravaud P, Steinfeld S et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6.
7. Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006;65:1033-7.
8. Bowman S, Barone F. Biologic treatments in Sjogren's syndrome. Presse Med 2012;41:e495-509.
9. Dass S, Bowman SJ, Vital EM et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4.
10. Meijer JM, Meiners PM, Vissink A et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
11. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014;160:233-42.
12. Brown S, Navarro Coy N, Pitzalis C et al. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome. BMC Musculoskelet Disord 2014;15:21.
13. Mariette X, Seror R, Quartuccio L et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015;74:526-31.
14. Seror R, Ravaud P, Mariette X et al. EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Ann Rheum Dis 2011;70:968-72.
15. Seror R, Ravaud P, Bowman SJ et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010;69:1103-9.
16. Seror R, Bootsma H, Saraux A et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2014 (in press); pii: annrheumdis-2014-206008. doi: 10.1136/ annrheumdis-2014-206008. [Epub ahead of print].
17. Meiners PM, Arends S, Brouwer E et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis 2012;71:1297-302.
18. Moerman RV, Arends S, Meiners PM et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis 2014;73:472-4.
19. Bowman SJ, Macfarlane GJ, Arthritis Research Campaign Data Monitoring Committee. Successful patient recruitment in investigator-led clinical trials. Rheumatology 2007;46:1207-8.
20. Ng WF, Bowman SJ, Griffiths B, UKPSSR study group. United Kingdom Primary Sjögren's Syndrome Registry: a united effort to tackle an orphan rheumatic disease. Rheumatology 2011;50:32-9.
21. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
22. Barry RJ, Sutcliffe N, Isenberg DA et al. The Sjögren's Syndrome Damage Index-a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome. Rheumatology 2008;47:1193-8.
23. Bowman SJ, St Pierre Y, Sutcliffe N et al. Estimating indirect costs in primary Sjögren's syndrome. J Rheumatol 2010;37:1010-5.
24. Baldini C, Pepe P, Quartuccio L et al. Primary Sjögren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 2014;53:839-44.
25. Bookman AA, Shen H, Cook RJ et al. Whole stimulated salivary flow: correlation with the pathology of inflammation and damage in minor salivary gland biopsy specimens from patients with primary Sjögren's syndrome but not patients with sicca. Arthritis Rheum 2011;63:2014-20.
26. El Miedany YM, Ahmed I, Mourad HG et al. Quantitative ultrasonography and magnetic resonance imaging of the parotid gland: can they replace the histopathologic studies in patients with Sjögren's syndrome? Joint Bone Spine 2004;71:29-38.
27. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21:S154-7.
28. Gottenberg JE, Ravaud P, Puechal X et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014;312:249-58.